JP6357292B2 - Ｃｎｋｓｒ１を阻害するための方法及び組成物 - Google Patents

Ｃｎｋｓｒ１を阻害するための方法及び組成物 Download PDF

Info

Publication number
JP6357292B2
JP6357292B2 JP2015548050A JP2015548050A JP6357292B2 JP 6357292 B2 JP6357292 B2 JP 6357292B2 JP 2015548050 A JP2015548050 A JP 2015548050A JP 2015548050 A JP2015548050 A JP 2015548050A JP 6357292 B2 JP6357292 B2 JP 6357292B2
Authority
JP
Japan
Prior art keywords
compound
cancer
alkyl
acid
available
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015548050A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016508969A (ja
JP2016508969A5 (enExample
Inventor
カークパトリック、ディー．、リン
インダーテ、マーティン
イーレ、ネイサン、ティー．
Original Assignee
フューシス セラピューティクス、インク．
フューシス セラピューティクス、インク．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フューシス セラピューティクス、インク．, フューシス セラピューティクス、インク． filed Critical フューシス セラピューティクス、インク．
Publication of JP2016508969A publication Critical patent/JP2016508969A/ja
Publication of JP2016508969A5 publication Critical patent/JP2016508969A5/ja
Application granted granted Critical
Publication of JP6357292B2 publication Critical patent/JP6357292B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
JP2015548050A 2012-12-14 2013-12-16 Ｃｎｋｓｒ１を阻害するための方法及び組成物 Active JP6357292B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737658P 2012-12-14 2012-12-14
US61/737,658 2012-12-14
PCT/US2013/075505 WO2014093988A2 (en) 2012-12-14 2013-12-16 Methods and compositions for inhibiting cnksr1

Publications (3)

Publication Number Publication Date
JP2016508969A JP2016508969A (ja) 2016-03-24
JP2016508969A5 JP2016508969A5 (enExample) 2017-02-23
JP6357292B2 true JP6357292B2 (ja) 2018-07-11

Family

ID=50935099

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015548050A Active JP6357292B2 (ja) 2012-12-14 2013-12-16 Ｃｎｋｓｒ１を阻害するための方法及び組成物

Country Status (7)

Country Link
US (1) US9340532B2 (enExample)
EP (1) EP2931280B1 (enExample)
JP (1) JP6357292B2 (enExample)
AU (1) AU2013358876B2 (enExample)
CA (1) CA2895162C (enExample)
MX (2) MX393754B (enExample)
WO (1) WO2014093988A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2895162C (en) 2012-12-14 2021-03-09 D. Lynn Kirkpatrick Methods and compositions for inhibiting cnksr1
US10227356B2 (en) 2015-04-20 2019-03-12 Phusis Therapeutics, Inc. Compounds, compositions and methods for inhibiting CNKSR1
WO2018125983A1 (en) 2016-12-30 2018-07-05 Mitobridge, Inc. Oxopyridine derivatives useful as aminocarboxymuconate semialdehyde decarboxylase (acmsd) inhibitors
CN110698411B (zh) * 2018-07-09 2023-05-09 四川大学 一类4-(胺烷基)酞嗪-1-酮类化合物、其制备方法和用途
US20230312482A1 (en) * 2020-07-28 2023-10-05 Mirati Therapeutics, Inc. Sos1 inhibitors
WO2022187804A1 (en) * 2021-03-02 2022-09-09 Icahn School Of Medicine At Mount Sinai Benzoxazolone inhibitors of inflammasomes
WO2024192873A1 (zh) * 2023-03-20 2024-09-26 杭州天玑济世生物科技有限公司 一类具有萘胺结构的小分子化合物的用途

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA775563A (en) 1968-01-09 Frank W. Horner Limited Hypoglycemic thiadiazoles
GB828963A (en) 1956-08-03 1960-02-24 Rhone Poulenc Sa Pharmaceutical compositions containing 2-p-aminobenzenesulphonamido-5-t-butyl-1, 3, 4-thiadiazole
US3821222A (en) 1971-11-22 1974-06-28 Chevron Res Hydrocarbyl sulfenylmercapto pyrimidines
US4017489A (en) 1975-07-10 1977-04-12 The Goodyear Tire & Rubber Company Process of preparing unsymmetrical disulfides
DE2556011A1 (de) 1975-12-12 1977-06-23 Merck Patent Gmbh Disulfide
IE47592B1 (en) * 1977-12-29 1984-05-02 Ici Ltd Enzyme inhibitory phthalazin-4-ylacetic acid derivatives, pharmaceutical compositions thereof,and process for their manufacture
GB2152497B (en) 1983-11-28 1987-08-05 Otsuka Kagaku Kk Process for the preparation of azetidinone derivatives
FR2573077B1 (fr) 1984-11-13 1987-02-13 Sanofi Sa Nouveaux derives thiosulfonates, leur procede de preparation ainsi que les compositions pharmaceutiques les contenant
US4939140A (en) * 1985-11-07 1990-07-03 Pfizer Inc. Heterocyclic oxophthalazinyl acetic acids
US4990523A (en) 1989-06-19 1991-02-05 A. H. Robins Company, Incorporated Treatment of chronic inflammatory joint disease with arylsulfonamides
GB9507415D0 (en) * 1994-06-08 1995-05-31 Zylepsis Ltd Production and uses of caffeic acid and derivatives thereof
US6139875A (en) 1998-09-29 2000-10-31 Eastman Chemical Company Aqueous enteric coating composition and low gastric permeability enteric coating
FR2815032B1 (fr) 2000-10-10 2003-08-08 Pf Medicament Nouveaux derives d'aminophenyle piperazine ou d'amino phenyle piperide inhibiteurs de proteines prenyl transferase ainsi que leurs preparations
WO2002083064A2 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
NZ531245A (en) * 2001-08-15 2005-09-30 Icos Corp 2H-phthalazin-1-ones and methods for use thereof
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
US20060142178A1 (en) 2002-04-08 2006-06-29 Barnett Stanley F Method of treating cancer
GB0215823D0 (en) * 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
JP4787155B2 (ja) 2003-06-24 2011-10-05 イシス イノベーション リミテッド タンパク質のジスルフィド結合形成およびグリコシル化の方法とそれに用いられる試薬
BRPI0412380A (pt) 2003-07-08 2006-09-19 Novartis Ag compostos de benzenossulfonilamino e composições farmacêuticas que contêm esses compostos
CA2559579A1 (en) 2004-03-19 2005-09-29 The Tapemark Company Thermoplastic films and methods for making
JP2007530589A (ja) 2004-03-26 2007-11-01 アンフォラ ディスカバリー コーポレーション 特定のトリアゾールを基礎とする化合物、組成物、およびそれらの使用
SE0402635D0 (sv) 2004-10-29 2004-10-29 Astrazeneca Ab Chemical compounds
DE102005011822A1 (de) * 2005-03-15 2006-09-21 Merck Patent Gmbh Phthalazinone
ATE487706T1 (de) 2005-10-06 2010-11-15 Sanofi Aventis Cyclische n-ä1,3,4ü-thiadiazol-2-yl- benzsulfonamide, verfahren zu deren herstellung und deren verwendung als arzneimittel
WO2007106391A1 (en) 2006-03-10 2007-09-20 Lymphosign Inc. Compounds for modulating cell proliferation, compositions and methods related thereto
KR20090017498A (ko) 2006-04-04 2009-02-18 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 Ｐｉ３ 키나제 길항물질
CA2674078C (en) 2006-12-26 2012-03-20 Femmepharma Holding Company, Inc. Topical administration of danazol
CA2721371C (en) 2008-04-14 2016-07-12 Arizona Board Of Regents On Behalf Of The University Of Arizona Small molecule inhibitors of the pleckstrin homology domain and methods for using same
WO2010085968A1 (en) * 2008-12-30 2010-08-05 European Molecular Biology Laboratory (Embl) Toluidine sulfonamides and their use as hif-inhibitors
CN102448951B (zh) * 2009-04-06 2017-05-10 安吉奥斯医药品有限公司 丙酮酸激酶m2调节剂、治疗组合物和相关使用方法
CA2773561A1 (en) 2009-09-14 2011-03-17 Phusis Therapeutics Inc. Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
KR20140027974A (ko) * 2011-04-05 2014-03-07 버텍스 파마슈티칼스 인코포레이티드 Ｔｒａ 키나제의 억제제로서 유용한 아미노피라진 화합물
CA2895162C (en) 2012-12-14 2021-03-09 D. Lynn Kirkpatrick Methods and compositions for inhibiting cnksr1

Also Published As

Publication number Publication date
US9340532B2 (en) 2016-05-17
WO2014093988A2 (en) 2014-06-19
US20150307482A1 (en) 2015-10-29
JP2016508969A (ja) 2016-03-24
MX372739B (es) 2020-05-06
AU2013358876B2 (en) 2018-05-10
WO2014093988A3 (en) 2014-08-07
EP2931280B1 (en) 2018-02-14
CA2895162A1 (en) 2014-06-19
MX393754B (es) 2025-03-24
CA2895162C (en) 2021-03-09
AU2013358876A1 (en) 2014-06-19
MX2015007608A (es) 2016-04-13
EP2931280A2 (en) 2015-10-21
EP2931280A4 (en) 2016-06-01

Similar Documents

Publication Publication Date Title
JP6357292B2 (ja) Ｃｎｋｓｒ１を阻害するための方法及び組成物
JP7789832B2 (ja) がんを治療するための組成物及び方法
Li et al. Discovery of N 1-(4-((7-Cyclopentyl-6-(dimethylcarbamoyl)-7 H-pyrrolo [2, 3-d] pyrimidin-2-yl) amino) phenyl)-N 8-hydroxyoctanediamide as a Novel Inhibitor Targeting Cyclin-dependent Kinase 4/9 (CDK4/9) and Histone Deacetlyase1 (HDAC1) against Malignant Cancer
JP2023159152A (ja) がんを治療するための組成物及び方法
ES2677874T3 (es) Tratamiento del cáncer con inhibidores de la cinasa TOR
TWI631950B (zh) 藉二氫吡𠯤并吡𠯤治療癌症
ES2678250T3 (es) Tratamiento del cáncer con inhibidores de quinasa TOR
US10391092B2 (en) Methods for treating cancer using dihydropyrazino-pyrazine compound combination therapy
TWI750539B (zh) 新穎藥物組成物及其用途
JP2018529742A (ja) Ｅｚｈ２阻害剤を用いた髄芽腫の処置方法
CN110652514A (zh) 第三代egfr抑制剂的制药用途
CA2983260C (en) Sulfonamide compounds, compositions and methods for inhibiting cnksr1
KR20250089532A (ko) 암 치료를 위한 serd의 조합
EP3064582A1 (en) RESISTANT MUTANT 90 kDA HEAT SHOCK PROTEIN
TW202116301A (zh) 藥物組合及其用途
US20230048888A1 (en) Use of triazolotriazine derivative in treatment of diseases
JP2023513016A (ja) Ｎｅｋ２阻害剤としてのアミノピリミジニルアミノベンゾニトリル誘導体
TW201217341A (en) Receptor-type kinase modulator and methods of treating polycystic kidney disease
WO2020087126A1 (en) Methods of treatment, prevention and diagnosis
EA044668B1 (ru) Композиции и способы для лечения рака
HK40037064A (en) Compositions and methods for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161214

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20161214

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20171117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171205

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180302

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180507

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180529

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180616

R150 Certificate of patent or registration of utility model

Ref document number: 6357292

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250